Jonas Paludo

3.3k total citations
150 papers, 1.2k citations indexed

About

Jonas Paludo is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Jonas Paludo has authored 150 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 65 papers in Pathology and Forensic Medicine and 41 papers in Genetics. Recurrent topics in Jonas Paludo's work include Lymphoma Diagnosis and Treatment (63 papers), CAR-T cell therapy research (45 papers) and Chronic Lymphocytic Leukemia Research (37 papers). Jonas Paludo is often cited by papers focused on Lymphoma Diagnosis and Treatment (63 papers), CAR-T cell therapy research (45 papers) and Chronic Lymphocytic Leukemia Research (37 papers). Jonas Paludo collaborates with scholars based in United States, Italy and China. Jonas Paludo's co-authors include Jesus Vera Aguilera, Narjust Duma, Yucai Wang, Aaron S. Mansfield, Alex A. Adjei, Stephen M. Ansell, Ronald S. Go, Konstantinos Leventakos, Candace L. Haddox and Miguel González Vélez and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jonas Paludo

136 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonas Paludo United States	16	611	295	253	208	167	150	1.2k
Sacha Satram‐Hoang United States	16	537 0.9×	187 0.6×	194 0.8×	152 0.7×	45 0.3×	48	1.0k
Silvia Dehler Switzerland	19	472 0.8×	200 0.7×	111 0.4×	197 0.9×	170 1.0×	43	1.4k
Shripad Banavali India	22	666 1.1×	193 0.7×	638 2.5×	177 0.9×	124 0.7×	170	2.0k
Charles F. LeMaistre United States	19	525 0.9×	199 0.7×	355 1.4×	132 0.6×	153 0.9×	48	1.2k
Lucio Gordan United States	14	625 1.0×	178 0.6×	68 0.3×	102 0.5×	77 0.5×	46	1.1k
Prasanth Ganesan India	18	352 0.6×	197 0.7×	207 0.8×	183 0.9×	40 0.2×	144	1.1k
Ranjan Pathak United States	20	408 0.7×	157 0.5×	112 0.4×	152 0.7×	136 0.8×	107	1.5k
April Teitelbaum United States	15	476 0.8×	89 0.3×	156 0.6×	58 0.3×	187 1.1×	31	960
Milayna Subar United States	17	1.1k 1.7×	690 2.3×	68 0.3×	267 1.3×	209 1.3×	33	1.6k
Hikmat Abdel‐Razeq Jordan	17	481 0.8×	140 0.5×	134 0.5×	113 0.5×	32 0.2×	155	1.2k

Countries citing papers authored by Jonas Paludo

Since Specialization

Citations

This map shows the geographic impact of Jonas Paludo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonas Paludo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonas Paludo more than expected).

Fields of papers citing papers by Jonas Paludo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonas Paludo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonas Paludo. The network helps show where Jonas Paludo may publish in the future.

Co-authorship network of co-authors of Jonas Paludo

This figure shows the co-authorship network connecting the top 25 collaborators of Jonas Paludo. A scholar is included among the top collaborators of Jonas Paludo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonas Paludo. Jonas Paludo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hou, Lifang, Leonidas C. Platanias, Stephen M. Ansell, et al.. (2025). Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States. Blood Advances. 9(6). 1463–1471.

Tun, Aung M., Yucai Wang, Seth Maliske, et al.. (2024). Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 109(7). 2186–2195. 4 indexed citations

Abbasi, Muhannad, Yi Lin, Jonas Paludo, et al.. (2024). Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies. Cardio-Oncology. 10(1). 91–91. 2 indexed citations

Wang, Jacqueline, Jihao Zhou, Han W. Tun, et al.. (2024). Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study. Blood. 144(Supplement 1). 1637–1637.

Tun, Aung M., Yucai Wang, Seth Maliske, et al.. (2024). Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy. Transplantation and Cellular Therapy. 30(10). 1001.e1–1001.e12. 1 indexed citations

Bansal, Radhika, Hassan B. Alkhateeb, Stephen M. Ansell, et al.. (2024). Metformin and cytokine release syndrome after immune effector cell therapy.. Journal of Clinical Oncology. 42(16_suppl). e14535–e14535.

Bansal, Radhika, Paschalis Vergidis, Pritish K. Tosh, et al.. (2024). Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 30(4). 455.e1–455.e7. 1 indexed citations

Abbasi, Muhannad, Mahmoud Ismayl, Abdullah Al‐Abcha, et al.. (2023). Cardiotoxicities of Novel Therapies in Hematological Malignancies: Monoclonal Antibodies and Enzyme Inhibitors. Current Problems in Cardiology. 48(8). 101757–101757. 1 indexed citations

Bock, Allison M., Jennifer Gile, Melissa C. Larson, et al.. (2023). Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer Journal. 13(1). 169–169. 3 indexed citations

10.

Abbasi, Muhannad, et al.. (2023). Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncology Practice. 19(6). 331–342. 9 indexed citations

11.

Villa, Diego, Aixiang Jiang, Carlo Visco, et al.. (2023). Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Advances. 7(16). 4576–4585. 11 indexed citations

12.

Breen, William G., Jason R. Young, Matthew Hathcock, et al.. (2023). Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity. Blood Cancer Journal. 13(1). 127–127. 12 indexed citations

13.

Moustafa, Muhamad Alhaj, Liuyan Jiang, Madiha Iqbal, et al.. (2022). Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. Clinical Lymphoma Myeloma & Leukemia. 22(8). e815–e825. 2 indexed citations

14.

Sidana, Surbhi, Cristine Allmer, Melissa C. Larson, et al.. (2022). Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncology Practice. 18(8). e1320–e1333. 6 indexed citations

15.

Khurana, Arushi, Abdullah S. Al Saleh, Tuan Truong, et al.. (2021). Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL). Transplantation and Cellular Therapy. 27(3). S416–S417. 1 indexed citations

16.

Khurana, Arushi, Matthew Hathcock, Thomas M. Habermann, et al.. (2021). Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin’s Lymphoma (NHL). Transplantation and Cellular Therapy. 27(3). S45–S47. 1 indexed citations

17.

Castellino, Alessia, Yucai Wang, Melissa C. Larson, et al.. (2021). Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances. 6(4). 1350–1360. 13 indexed citations

18.

Iqbal, Madiha, Jonas Paludo, Allison Rosenthal, et al.. (2021). Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 22(2). e89–e95. 2 indexed citations

19.

Castellino, Alessia, Aung M. Tun, Yucai Wang, et al.. (2021). Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer Journal. 11(1). 8–8. 7 indexed citations

20.

Khurana, Arushi, Radhika Bansal, Matthew Hathcock, et al.. (2021). Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience. Blood. 138(Supplement 1). 3842–3842. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact